by jtcir-auto | Nov 9, 2023 | Press Releases
– Launch of Ghryvelin™ in a number of key countries in the European Economic Area – Approval of Macrilen® in South Korea in September – Ended the quarter with $38.8 million in cash, expected to fund operations and advancement of priority...
by jtcir-auto | Oct 11, 2023 | Press Releases
– Live moderated webcast with Klaus Paulini, Chief Executive Officer of Aeterna Zentaris on Wednesday, October 25th at 10:00 AM ET TORONTO, ONTARIO, Oct. 11, 2023 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or...
by jtcir-auto | Sep 5, 2023 | Press Releases
TORONTO, ONTARIO, Sept. 05, 2023 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of...
by jtcir-auto | Sep 5, 2023 | Press Releases
TORONTO, ONTARIO, Sept. 05, 2023 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of...
by jtcir-auto | Aug 9, 2023 | Press Releases
Ended the quarter with $42.2 million in cash, expected to fund operations into 2025Driving patient recruitment for Phase 3 DETECT trial for the diagnosis of Childhood Onset Growth Hormone Deficiency TORONTO, ONTARIO, Aug. 09, 2023 (GLOBE NEWSWIRE) — Aeterna...
by jtcir-auto | Aug 9, 2023 | Press Releases
Ended the quarter with $42.2 million in cash, expected to fund operations into 2025Driving patient recruitment for Phase 3 DETECT trial for the diagnosis of Childhood Onset Growth Hormone Deficiency TORONTO, ONTARIO, Aug. 09, 2023 (GLOBE NEWSWIRE) — Aeterna...